>

Regeneron Leadership

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:4em;padding-top: 25px;;'>RE</div>
REGN -- USA Stock  

Fiscal Quarter End: March 31, 2020  

Regeneron Pharmaceuticals employes about 8.1 K people. The company is managed by 26 executives with total tenure of roughly 278 years, averanging almost 10.0 years of service per executive having 311.0 employee per reported executive. Inspection of Regeneron Pharmaceuticals management performance can provide insight into the corporation performance. Note, an employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Regeneron Pharmaceuticals future performance. Additionally, take a look at Your Equity Center.
Equity
Refresh
  Leonard Schleifer  CEO
President CEO, Director
  Roy Vagelos  Chairman
Chairman of the Board
  Peter Powchik  President
Senior Vice President - Clinical Development
Return on Sales

Regeneron Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of 13.61 % which means that it generated profit of $13.61 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 18.87 % meaning that it created $18.87 on every $100 dollars invested by stockholders.

Regeneron Pharmaceuticals Workforce Comparison

Regeneron Pharmaceuticals is rated third in number of employees category among related companies. The total workforce of Biotechnology industry is at this time estimated at about 62,425. Regeneron Pharmaceuticals retains roughly 8,100 in number of employees claiming about 13% of stocks in Biotechnology industry.

Regeneron Pharmaceuticals Profit Margins

The company has Profit Margin (PM) of 29.03 % which can be a sign that it executes well on its competitive strategies and has a good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 32.16 % which suggests for every 100 dollars of sales it generated a net operating income of 0.32.

Regeneron Pharmaceuticals Insider Trading

Regeneron Pharmaceuticals Benchmark Summation

Operator
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was zero with a total number of output elements of sixty-one. Regeneron Pharmaceuticals Price Series Subtraction is a subtraction of Regeneron Pharmaceuticals price series from its benchmark/peer.. View also all equity analysis or get more info about price series subtraction math operators indicator.

Regeneron Pharmaceuticals Stakeholders

Leonard Schleifer President CEO, Director
Roy Vagelos Chairman of the Board
Peter Powchik Senior Vice President - Clinical Development
Jay Markowitz Senior Vice President - Portfolio Management
Marion McCourt Senior Vice President and Head of Commercial
George Yancopoulos Chief Scientific Officer and President - Regeneron Laboratories, Director
Joseph LaRosa Senior Vice President General Counsel, Secretary
Daniel Plew Senior Vice President General Manager - Industrial Operations and Product Supply
Michael Aberman Vice President - Strategy
Douglas McCorkle Vice President Controller, Assistant Treasurer
Christopher Fenimore Vice President Controller
Robert Landry CFO and Sr. VP of Fin.
Neil Stahl Executive VP of RandD
Robert Terifay Sr. VP of Commercial
Charles Baker Independent Director
Joseph Goldstein Independent Director
Anthony Coles Independent Director
George Sing Independent Director
Michael Brown Independent Director
Christine Poon Independent Director
Huda Zoghbi Director
Bonnie Bassler Director
Alfred Gilman Independent Director
Marc TessierLavigne Independent Director
Arthur Ryan Independent Director
Manisha Narasimhan IR Contact

Regeneron Pharmaceuticals Manpower Efficiency

Return on Regeneron Pharmaceuticals Manpower

Revenue Per Employee840.9 K
Revenue Per Executive293.1 M
Net Income Per Employee281.8 K
Net Income Per Executive82.3 M
Working Capital Per Employee259.7 K
Working Capital Per Executive80.9 M

Per Employee

Regeneron Pharmaceuticals Per Employee Growth Over Time

Net Income Per Employee
Revenue Per Employee
Additionally, take a look at Your Equity Center. Please also try Premium Stories module to follow macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Company logos by clearbit